Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Cynosure Inc Receives FDA Clearance For PicoSure
Cynosure Inc announced that it has received FDA 510(k) clearance to market the PicoSure laser workstation for the removal of tattoos and benign pigmented lesions. The Company expects to sell PicoSure initially through its U.S. direct sales force to aesthetic dermatologists and plastic surgeons beginning in early 2013.
Latest Developments for Cynosure Inc
- Cynosure Inc Signs Definitive Agreement To Acquire Palomar Medical Technologies
- Cynosure Inc Announces Closing of Public Offering
- Cynosure Inc Prices Public Offering Of Class A Common Stock; Sale Of Shares By El.En. S.p.A
- Cynosure, Inc. Receives FDA Clearance For At-Home Device For Treatment of Wrinkles
Latest Key Developments in Advanced
- Waters Corp Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates; Reaffirms FY 2013 EPS Guidance-Conference Call
- Hologic Inc Updates FY 2013 Guidance To A Range In Line With Analysts' Estimates-Conference Call
- Arrhythmia Research Technology Inc Issues Q1 2013 Guidance; Announces Delay In Finalizing First Quarter Of 2013 Results
- Biosensors International Group Ltd Announces Incorporation Of New Subsidiaries
- Share this
- Link this
- Digg this
Follow Reuters